During the last session, Spero Therapeutics Inc. (NASDAQ:SPRO)’s traded shares were 0.19 million, with the beta value of the company hitting 1.97. At the end of the trading day, the stock’s price was $0.80, reflecting an intraday gain of 1.63% or $0.01. The 52-week high for the SPRO share is $19.87, that puts it down -2383.75 from that peak though still a striking 15.0% gain since the share price plummeted to a 52-week low of $0.68. The company’s market capitalization is $27.87M, and the average intraday trading volume over the past 10 days was 0.18 million shares, and the average trade volume was 407.26K shares over the past three months.
Spero Therapeutics Inc. (SPRO) received a consensus recommendation of an Overweight from analysts. That translates to a mean rating of 2.30. SPRO has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.89.
Spero Therapeutics Inc. (NASDAQ:SPRO) trade information
Spero Therapeutics Inc. (SPRO) registered a 1.63% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.63% in intraday trading to $0.80 this Friday, 08/05/22, hitting a weekly high. The stock’s 5-day price performance is 9.26%, and it has moved by -0.70% in 30 days. Based on these gigs, the overall price performance for the year is -94.36%. The short interest in Spero Therapeutics Inc. (NASDAQ:SPRO) is 0.56 million shares and it means that shorts have 1.36 day(s) to cover.
The consensus price target of analysts on Wall Street is $5.67, which implies an increase of 85.89% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $2.00 and $10.00 respectively. As a result, SPRO is trading at a discount of -1150.0% off the target high and -150.0% off the low.
Spero Therapeutics Inc. (SPRO) estimates and forecasts
Statistics show that Spero Therapeutics Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Spero Therapeutics Inc. (SPRO) shares have gone down -92.49% during the last six months, with a year-to-date growth rate less than the industry average at -8.25% against 1.00. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to shrink -41.30% this quarter and then jump 22.90% in the quarter after that. In the rating firms’ projections, revenue will decrease -69.50% compared to the previous financial year.
Revenue for the current quarter is expected to be $1.15 million as predicted by 2 analyst(s). Meanwhile, a consensus of 2 analyst(s) estimates revenue growth to $1.16 million by the end of Sep 2022.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -6.20%. While earnings are projected to return 17.50% in 2022, the next five years will return 36.90% per annum.
Spero Therapeutics Inc. is due to release its next quarterly earnings between March 09 and March 14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Spero Therapeutics Inc. (NASDAQ:SPRO)’s Major holders
Spero Therapeutics Inc. insiders own 16.03% of total outstanding shares while institutional holders control 61.37%, with the float percentage being 73.08%. Aquilo Capital Management, LLC is the largest shareholder of the company, while 138 institutions own stock in it. As of Mar 30, 2022, the company held over 5.28 million shares (or 16.09% of all shares), a total value of $45.95 million in shares.
The next largest institutional holding, with 1.79 million shares, is of Blackrock Inc.’s that is approximately 5.47% of outstanding shares. At the market price on Mar 30, 2022, these shares were valued at $15.61 million.
Also, the Mutual Funds coming in first place with the largest holdings of Spero Therapeutics Inc. (SPRO) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Mar 30, 2022 indicates that Vanguard Total Stock Market Index Fund owns about 0.68 million shares. This amounts to just over 2.07 percent of the company’s overall shares, with a $5.9 million market value. The same data shows that the other fund manager holds slightly less at 0.39 million, or about 1.18% of the stock, which is worth about $3.37 million.